Effect of Celecoxib Versus Placebo Before and After Knee Surgery on Overall Use of Analgesics After Surgery
Public ClinicalTrials.gov record NCT00633438. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Placebo-Controlled, Randomized Comparison Study of the Efficacy of Celebrex 400 mg Single Dose Pre and Celebrex 200 mg Post Ambulatory Arthroscopic Knee Surgery for Total Analgesic Use After Surgery
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To compare total analgesic use at 24 hours after arthroscopic knee surgery in celecoxib-treated versus placebo-treated patients
Study identification
- NCT ID
- NCT00633438
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 204 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2004 (Type not available)
- Primary completion
- Not listed
- Completion
- Jun 2004 (Actual)
- Last update posted
- Feb 21, 2021
2004
United States locations
- U.S. sites
- 18
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Phoenix | Arizona | 85023 | — |
| Pfizer Investigational Site | St. Petersburg | Florida | 33713 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21218 | — |
| Pfizer Investigational Site | Timonium | Maryland | 21093 | — |
| Pfizer Investigational Site | Springfield | Massachusetts | 01104 | — |
| Pfizer Investigational Site | Springfield | Massachusetts | 01107 | — |
| Pfizer Investigational Site | Springfield | Massachusetts | 01109 | — |
| Pfizer Investigational Site | Springfield | Massachusetts | 01199 | — |
| Pfizer Investigational Site | Springfield | Missouri | 65807 | — |
| Pfizer Investigational Site | Columbia | South Carolina | 29202 | — |
| Pfizer Investigational Site | Columbia | South Carolina | 29204 | — |
| Pfizer Investigational Site | Columbia | South Carolina | 29212 | — |
| Pfizer Investigational Site | Orangeburg | South Carolina | 29110 | — |
| Pfizer Investigational Site | Johnson City | Tennessee | 37601 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78205 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78209 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78240 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00633438, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 21, 2021 · Synced Nov 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00633438 live on ClinicalTrials.gov.